QurAlis
Edit

QurAlis

https://quralis.com/
Last activity: 16.09.2024
Active
Categories: BioTechDrugHealthTechHumanLife
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.
Followers
346
Followers
2.99K
Mentions
41
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $135.5M
Founded date: 2016

Investors 6

Funding Rounds 3

DateSeriesAmountInvestors
10.03.2023Series B$88M-
22.05.2020Series A$42M-
20.11.2018Seed$5.5M-

Mentions in press and media 41

DateTitleDescription
16.09.2024Pioneering New Frontiers in ALS and Cancer Treatment: The Role of QRL-101 and mIDH1 InhibitorsIn the realm of medical science, innovation is the lifeblood that fuels progress. Two recent developments stand out: QurAlis Corporation's QRL-101 for ALS and Vazyme's contributions to mIDH1 cancer treatment. Both represent significant stri...
10.09.2024QurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALSQRL-101 aims to reduce hyperexcitability-induced neurodegeneration, which is present in approximately 50 percent of all ALS patients Completed Phase 1 single-ascending dose (SAD) clinical trial of QRL-101 enrolled 88 participants; no report...
12.06.2024Latest Updates of Viva Biotech's Portfolio CompaniesHONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies...
11.06.2024QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of DirectorsIndustry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals Former Karuna CFO Brown brings more than...
03.06.2024QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTDQRL-204 is a splice-switching ASO generated through QurAlis’ FlexASO™ Platform; represents Lilly’s first program targeting UNC13A in ALS and FTD Parties to also collaborate to leverage QurAlis’ ALS and ASO development expertise to advance Q...
04.03.2024QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal DementiaUNC13A is an essential regulator of neurotransmitter release at synapses; mis-splicing is a critical RNA alteration occurring in up to 63 percent of all ALS patients and up to one-third of all FTD cases Preclinical data to be featured in a ...
20.12.2023Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory missionWe've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st...
06.04.2023QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALSFirst patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients
04.04.2023Latest Updates of 6 Viva's Portfolio CompaniesHONG KONG, April 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies...
10.03.2023QurAlis Closes $88 Million Series B CAMBRIDGE, MA, QurAlis Corporation, a clinical-stage biotechnology company, has closed an oversubscribed $88 million Series B financing, led by EQT Life Sciences. >> Click here for more funding data on QurAlis >> To export Q...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In